Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent

Clinical and Experimental Immunology

Volumn 168, Issue 3, 2012, Pages 261-267

  Yang, C Y ^a   Leung, P S C ^a   Yang, G X ^a   Kenny, T P ^a   Zhang, W ^a   Coppel, R ^b   Norman, G L ^c   Ansari, A A ^d   Mackay, I R ^b   Worman, H J ^e   Gershwin, M E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MONASH UNIVERSITY   (Australia)

^c INOVA DIAGNOSTICS INC   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NewYork Presbyterian Hospital   (United States)

Author keywords

AMA; ANA; Autoantibodies; Cytokines; Gp210

Indexed keywords

ANTINUCLEAR ANTIBODY; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23P19; INTERLEUKIN 6; MITOCHONDRION ANTIBODY; NUCLEAR PROTEIN; PROTEIN GP210; PROTEIN SP100; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; GENE DELETION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, NUCLEAR; AUTOANTIGENS; CELLS, CULTURED; CYTOKINES; DISEASE MODELS, ANIMAL; EPITOPES; HUMANS; LIVER CIRRHOSIS, BILIARY; MICE; MICE, TRANSGENIC; NUCLEAR PORE COMPLEX PROTEINS; SEQUENCE DELETION;

EID: 84859939127     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04577.x     Document Type: Article

References (55)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353:1261-73.
2. Rose NR, Mackay IR. The autoimmune diseases, 4th edn. St Louis, MO/London: Elsevier Academic Press, 2006.
3. Worman HJ, Courvalin JC. Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev 2003; 2:211-17.
4. Lassoued K, Brenard R, Degos F etal. Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with primary biliary cirrhosis. Gastroenterology 1990; 99:181-6.
5. Lozano F, Pares A, Borche L etal. Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis. Hepatology 1988; 8:930-8.
6. Lassoued K, Guilly MN, Andre C etal. Autoantibodies to 200kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis. Clin Exp Immunol 1988; 74:283-8.
7. Ruffatti A, Arslan P, Floreani A etal. Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis. J Clin Immunol 1985; 5:357-61.
8. Courvalin JC, Lassoued K, Bartnik E, Blobel G, Wozniak RW. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest 1990; 86:279-85.
9. Nickowitz RE, Worman HJ. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210. J Exp Med 1993; 178:2237-42.
10. Szostecki C, Krippner H, Penner E, Bautz FA. Autoimmune sera recognize a 100kD nuclear protein antigen (sp-100). Clin Exp Immunol 1987; 68:108-16.
11. Szostecki C, Guldner HH, Netter HJ, Will H. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J Immunol 1990; 145:4338-47.
12. Selmi C, Mackay IR, Gershwin ME. The autoimmunity of primary biliary cirrhosis and the clonal selection theory. Immunol Cell Biol 2011; 89:70-80.
13. Blüthner M, Schäfer C, Schneider C, Bautz FA. Identification of major linear epitopes on the sp100 nuclear PBC autoantigen by the gene-fragment phage-display technology. Autoimmunity 1999; 29:33-42.
14. Cavazzana I, Ceribelli A, Taraborelli M etal. Primary biliary cirrhosis-related autoantibodies in a large cohort of Italian patients with systemic sclerosis. J Rheumatol 2011; 38:2180-5.
15. Liu H, Norman GL, Shums Z etal. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 2010; 35:436-42.
16. Nickowitz RE, Wozniak RW, Schaffner F, Worman HJ. Autoantibodies against integral membrane proteins of the nuclear envelope in patients with primary biliary cirrhosis. Gastroenterology 1994; 106:193-9.
17. Nakamura M, Kondo H, Mori T etal. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45:118-27.
18. Wesierska-Gadek J, Penner E, Battezzati PM etal. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43:1135-44.
19. Itoh S, Ichida T, Yoshida T etal. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastro Hepatol 1998; 13:257-65.
20. Muratori P, Muratori L, Ferrari R etal. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003; 98:431-7.
21. Invernizzi P, Podda M, Battezzati PM etal. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001; 34:366-72.
22. Ueno Y, Ambrosini YM, Moritoki Y, Ridgway WM, Gershwin ME. Murine models of autoimmune cholangitis. Curr Opin Gastroenterol 2010; 26:274-9.
23. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12:171-81.
24. Oertelt S, Lian Z-X, Cheng C-M etal. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006; 177:1655-60.
25. Ghilardi N, Kljavin N, Chen Q, Lucas S. Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol 2004; 172:2827-33.
26. Züchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology 1997; 26:1123-30.
27. Bandin O, Courvalin JC, Poupon R, Dubel L, Homberg JC, Johanet C. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 1996; 23:1020-4.
28. Tartakovsky F. Detection of Gp210 autoantibodies in primary biliary cirrhosis using a recombinant protein containing the predominant autoepitope. Hepatology 1995; 21:495-500.
29. Manuel Lucena J, Montes Cano M, Luis Caro J etal. Comparison of two ELISA assays for anti-Sp100 determination. Ann NY Acad Sci 2007; 1109:203-11.
30. Szostecki C, Will H, Netter HJ, Guldner HH. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand J Immunol 1992; 36:555-64.
31. Yoshida K, Yang G-X, Zhang W etal. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 2009; 50:1494-500.
32. Dardalhon V, Korn T, Kuchroo VK, Anderson AC. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008; 31:252-6.
33. Hunter CA. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005; 5:521-31.
34. Matusevicius D, Kivisäkk P, He B etal. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5:101-4.
35. Aarvak T, Chabaud M, Miossec P. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999; 162:1246-51.
36. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006; 18:670-5.
37. Bettelli E, Carrier Y, Gao W etal. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8.
38. Barak V, Selmi C, Schlesinger M etal. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun 2009; 33:178-82.
39. Nagano T, Yamamoto K, Matsumoto S etal. Cytokine profile in the liver of primary biliary cirrhosis. J Clin Immunol 1999; 19:422-7.
40. Tanaka A, Quaranta S, Mattalia A etal. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J Hepatol 1999; 30:826-9.
41. Zhang W, Tsuda M, Yang G-X etal. Deletion of interleukin-6 in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis. Hepatology 2010; 52:215-22.
42. Muraguchi A, Hirano T, Tang B etal. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167:332-44.
43. Hirano T, Yasukawa K, Harada H etal. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324:73-6.
44. Moritoki Y, Zhang W, Tsuneyama K etal. B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis. Gastroenterology 2009; 136:1037-47.
45. Invernizzi P, Lleo A, Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 2007; 27:161-72.
46. Granito A, Muratori P, Muratori L etal. Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther 2006; 24:1575-83.
47. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005; 25:298-310.
48. Bogdanos D. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003; 98:241-3.
49. Muratori P, Granito A, Ferri S etal. Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis. Autoimmunity 2009; 42:224-7.
50. Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 2008; 12:261-76, vii.
51. Rigopoulou EI, Davies ET, Pares A etal. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005; 54:528-32.
52. Muratori P, Muratori L, Cassani F etal. Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 2002; 127:172-5.
53. Hu C-J, Zhang F-C, Li Y-Z, Zhang X. Primary biliary cirrhosis: what do autoantibodies tell us? World J Gastroenterol 2010; 16:3616-29.
54. Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010; 55:2144-61.
55. Nakamura M, Takii Y, Ito M etal. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. J Autoimmun 2006; 26:138-45.